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Introduction
Hospitals and medical centers often cite
compassion as a core value in their mission
statements. In contrast, the importance of
compassion in global health is rarely
acknowledged, even though it is a signif-
icant source of motivation and sustenance
for those working in the field. The Global
Programme to Eliminate Lymphatic Fila-
riasis (GPELF) provides an illustrative
example of the role and promise of
compassion in global health. It was
established in 1998 to alleviate and
prevent immense human suffering caused
by the neglected tropical disease (NTD)
lymphatic filariasis (LF).
From its beginning, the GPELF was
conceived as having two ‘‘pillars’’: one to
interrupt transmission of the parasites that
cause LF and the other to care for those
who already have LF-related disease [1].
Inclusion of a morbidity management
pillar distinguished the GPELF from
efforts to eradicate smallpox, polio, and
Guinea worm disease, which focused
primarily, if not exclusively, on interrupt-
ing transmission. This two-pronged ap-
proach was initially criticized on the basis
that efforts to reduce the suffering of those
affected would divert attention and re-
sources from the principal goal of stopping
LF transmission [2].
Despite these reservations, the GPELF
adopted morbidity management for three
main reasons. First, the World Health
Assembly (WHA) resolution that launched
the GPELF (WHA 50.29) called for
eliminating LF ‘‘as a public health prob-
lem.’’ The public health problem in
question was not microfilaremia, but
rather the stigmatizing and disfiguring
conditions of lymphedema, affecting some
15 million persons, and hydrocele, affect-
ing some 25 million men. Second, it was
thought that providing clinical care to
those who already had LF-related disease
could enhance the acceptability of preven-
tive chemotherapy to interrupt transmis-
sion. Cantey and colleagues recently
documented this beneficial effect in a
study from Orissa, India [3]. Finally,
and most importantly, relieving suffer-
ing through morbidity management was
considered the right thing to do. Compas-
sion demanded it.
Compassion and the GPELF
Social psychology teaches that compas-
sion is comprised of three key elements:
cognitive awareness, emotional resonance,
and compassionate action. The GPELF is
characterized by all three. First, a com-
passionate response to suffering requires
that one first be aware of its existence. In a
speech to the Centers for Disease Control
and Prevention (CDC) in 1984, Bill Foege
said: ‘‘If we are to maintain the reputation
this institution now enjoys, it will be
because in everything we do, behind
everything we say, as the basis for every
program decision we make—we will be
willing to see faces.’’ This was an extraor-
dinary message for a major public health
institution with responsibilities for the
health of populations, not individuals.
The CDC’s reputation would depend not
on programmatic effectiveness, measur-
able outcomes, or epidemiologic prowess,
but on compassion—the willingness of its
employees, collectively, to see the faces of
suffering.
Many who established the GPELF had
studied LF as scientists and they were
acutely aware of the personal suffering,
stigmatization, and disability that it
caused. They had seen the faces—and
could not forget them. Inspired by the
pioneering clinical work of Dr. Gerusa
Dreyer in Brazil [4] and Professor R.K.
Shenoy in India [5], they insisted that
priority be given to relieving LF-related
suffering. During the past two decades,
our collective awareness of the magnitude
and nature of this suffering has grown
tremendously, thanks to excellent studies
by social scientists in Ghana, Brazil, Haiti,
the Dominican Republic, India, and
elsewhere (summarized in [6]).
Second, compassion requires emotional
attunement or empathy—the ability to feel
the suffering of the other. The LF program
has engaged the emotions since it began. A
1997 booklet by the World Health Orga-
nization (WHO) that promoted the cause
of LF elimination was punctuated with
sentences from a letter by a Ghanaian
woman with advanced LF-related lymph-
edema [7]. ‘‘Dear sir,’’ she begins, ‘‘I am
writing with the hope that you can help
me.’’ A few pages later, she continues: ‘‘I
kneel and plead to be touched by your
innermost heart for a humanitarian feel-
ing, to try and do your best to help me.’’
Although the role of emotion as a
motivating force, either individually or
collectively, is rarely discussed, virtually
everyone who is actively engaged in LF
elimination has a story, a lived experience
of human suffering that was deeply
moving—and that lies at the core of their
motivation for the work.
Third, compassion is characterized by
action. The Fourteenth Dalai Lama said
that compassion ‘‘is not just a wish to see
sentient beings free from suffering, but an
immediate need to intervene and actively
engage, to try to help…A person who has
attained stability in his or her compassion
training…should now be out, running
around like a mad dog, actively engaged
in acts of compassion’’ [8]. By any
standard, the action mobilized by the
GPELF to eliminate LF-related suffering
for future generations has been ‘‘mad dog’’
impressive. Some 3.9 billion preven-
tive chemotherapy treatments have been
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delivered since 2001. The GPELF is one
of the most rapidly upscaling programs in
public health history, having engaged
hundreds of thousands of workers and
now treating more than 500 million
persons each year [9].
Are We Seeing the Faces?
Unfortunately, the morbidity manage-
ment pillar, which WHO describes as
‘‘rooted in compassion’’ [10], has not
fared as well. In 2011, 53 of 73 LF-
endemic countries had preventive chemo-
therapy programs, while only 27 reported
activities in morbidity management [10].
Several reasons likely contribute to this.
Preventive chemotherapy has proven such
a powerful intervention for interrupting
LF transmission that most of the attention
and resources in the GPELF have been
devoted to scaling it up. Because of its
success, preventive chemotherapy has
become the overriding organizing princi-
ple not only for the elimination of LF, but
also for the control of other NTDs [11,12].
In addition, recommended procedures
and guidelines for management of hydro-
cele and lymphedema in LF-endemic
areas were not well-established when the
GPELF began. Further, effective national
programs to manage lymphedema and
hydrocele require extensive collaboration
with clinical health services, beyond the
purview and experience of many LF
program managers. A more nuanced and
sophisticated matrix approach toward LF
morbidity management is emerging that
mobilizes surgical services to manage
urogenital LF and integrates lymphedema
management with clinical care for condi-
tions such as diabetic foot, leprosy, and
Buruli ulcer [13]. In many areas, this
integrated approach, although not ‘‘solely
owned’’ by the LF program, will be
essential for the LF program to achieve
its goals.
A more subtle and pervasive reason for
the slow uptake of morbidity management
in the GPELF lies in the corrosive forces
that inhibit and obstruct compassion in
many global health programs. Sustaining
the empathic connection required for
compassion—seeing the faces behind the
numbers—is difficult when working to
improve the health of hundreds of millions
of people, across great geographic distanc-
es. What does it mean to have compassion
for entire populations? The global scope of
the LF program requires the collaboration
of many complex organizations, often with
competing agendas and historic rivalries.
Motivations other than compassion, such
as economic profit, political and military
hegemony, and personal ambition, are
notoriously active. Our collective silence
on compassion in our work isolates us as
individuals and allows these other forces to
operate unchallenged.
Addressing the Challenges
Much remains to be done if the 2020
target for LF elimination is to be met [10].
In addition to addressing the remaining
technical, logistical, and financial chal-
lenges, it will be necessary to simulta-
neously attend to four pairs of activities,
each of which holds the tension of
paradox. First, we need to maintain focus
on eliminating transmission and expand
our peripheral vision to include, to a much
greater extent, those with LF disease. The
two pillars are complementary and mutu-
ally reinforcing, not conflicting. Second,
extending the benefits of the GPELF to
those who currently suffer from LF-related
disease will require national LF elimina-
tion programs that are cohesive and
unified and that engage different sectors
of the health care system—a more sophis-
ticated and collaborative approach. Third,
we need to be able to see the faces and the
numbers—and to do this at the same time
[14]. Finally, we need to combine com-
passion for individuals with action at the
population level.
How might we begin to see both the
faces and the numbers, to combine
compassion for individuals with action at
the population level? We might start by
sharing our stories, by venturing to speak
more openly about the compassion that
motivates our work and sustains our
spirits. Many of us find that travel to the
field, literally to ‘‘see the faces,’’ revitalizes
our efforts to improve the health of
populations. We keep photos in our
workplace that remind us of individuals
whose lives have touched us. As we break
our collective silence on compassion, other
possibilities and practices will undoubtedly
emerge.
The late Steve Ben Israel, an American
comedian, anarchist, and performance
artist, said that the intent of his life’s work
was to ‘‘foment a mass uprising of
compassion’’ [15]. While the GPELF
has not fully extended the benefits it
initially promised to those with LF-
related disease, as a global response to
human suffering, it represents a spectac-
ular—if unfinished—mass uprising of
compassion. By connecting more deeply
with the compassionate impulse within
us, by cultivating the capacity to be fully
present to the faces of suffering, we will
be better equipped, individually and
collectively, to realize the GPELF’s tre-
mendous potential.
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